Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HeraMED.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Proteomics jumps 13pc on diabetes test
Health & Biotech
ASX Health Stocks: HeraMed jumps 11pc on survey results, while Acrux seeks FDA approval for acne gel
Tech
ASX Tech Stocks: ESG platform Envirosuite (ASX:EVA) up 8.33% with plans to accelerate US growth
Health & Biotech
HeraMED signs paid pilot with Obstetrix Medical Group, providers of care and diagnostics to 1 in 4 babies born in US
News
April Winners Column: Resources re-takes the mantle, led by one stock that gained nearly 500pc
Health & Biotech
HeraMED secures landmark commercial agreement with Joondalup Health Campus
Health & Biotech
Heart disease is becoming a bigger problem but these ASX stocks are trying to help with it
Health & Biotech
Leading scientific publication backs HeraMED’s foetal heartbeat monitor
Health & Biotech
Altor Capital has high conviction on these 4 medtech plays for 2021
Health & Biotech
Why HeraMED’s HeraBEAT device could replace CTG machines in emerging economies
Health & Biotech
Mayo Clinic approves clinical study of HeraMED’s HeraBEAT device
Health & Biotech
HeraMED taps into US employee benefit industry with Teleperinatal pilot
News
10 at 10: These ASX stocks have found their voice this morning
Health & Biotech
HeraMED taps into US healthcare market with eCare21 partnership
Stockhead TV
Health tech plays are seeing tectonic shifts in customer growth
Health & Biotech
Successful clinical study for HeraBEAT device showcases its telehealth application
Health & Biotech
